Trial Profile

PRiZM+: a Phase II platform study of zanubrutinib monotherapy and combination therapy for relapsed and refractory primary central nervous system lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zanubrutinib (Primary)
Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
Focus Therapeutic Use
Acronyms PRiZM+:

Most Recent Events

28 Feb 2023 Planned End Date changed from 30 Jun 2025 to 20 Oct 2026.
28 Feb 2023 Recruitment completion is expected on 20 Oct 2025, according to ISRCTN: Current Controlled Trials.
03 Jun 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com